Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

18 Jun 2020 17:30

RNS Number : 4186Q
Tiziana Life Sciences PLC
18 June 2020
 

Tiziana Life Sciences PLC

 

("Tiziana" or the "Company")

 

Directorate Change

 

 

London / New York, 18 June 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces Gregor MacRae is standing down as a director of the Company with immediate effect.

 

Gabriele Cerrone, Chairman of Tiziana, said "I thank Gregor for his contribution to the Board and the Company and wish him well in his other interests. We are currently in the process of recruiting a new, seasoned non-executive director with extensive NASDAQ audit committee experience and hope to make a formal announcement shortly".

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further enquiries: 

United Kingdom:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder 

+44 (0)20 7493 2379

 

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner 

 

 

+44 (0)20 7213 0880

Optiva Securities Limited (Broker)

Robert Emmet

+ 44 (0)20 3981 4173

 

United States:

Investors -

CORE IR

(516) 222-2560

ir@coreir.com

MediaJules Abraham

CORE IR

(917) 885-7378

julesa@coreir.com

For more information go to http://www.tizianalifesciences.com 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAGPUMCQUPUGCR
Date   Source Headline
28th May 20197:00 amRNS9th Annual LD Micro Invitational
7th May 20197:00 amRNSNotice of AGM
2nd May 20197:00 amRNSDirector/PDMR Shareholding
1st May 20197:00 amRNSUpdate on IND Application
25th Apr 20195:00 pmRNSDirector/PDMR Shareholding
24th Apr 201912:55 pmRNSReissue: Interim Clinical Data
24th Apr 20197:00 amRNSInterim Clinical Data
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
4th Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSIND Application Submitted for NASH Oral Treatment
7th Feb 20197:00 amRNSDirectorate Change
11th Dec 20187:00 amRNSExercise of Warrants & Issue of Equity
3rd Dec 20187:00 amRNSMilciclib HCC Phase IIa Trial Enrollment Completed
28th Nov 20187:00 amRNSForalumab: Phase 1 Trial with Nasal Administration
27th Nov 20187:00 amRNSHolding(s) in Company
26th Nov 20187:00 amRNSStatement re: ADSs
23rd Nov 20185:00 pmRNSClosing of Offering and Total Voting Rights
20th Nov 20187:30 amRNSDiscounted exercise prices of outstanding warrants
20th Nov 20187:00 amRNSOffer Pricing, Nasdaq Listing & Loan Conversion
18th Oct 20187:15 amRNSAmended Registration Statement filed with the SEC
16th Oct 20187:00 amRNSMilciclib synergistic activity presented at AASLD
25th Sep 20187:00 amRNSTiziana announces Offering & Application to Nasdaq
24th Sep 20187:03 amRNSInterim Results for Six Months Ended 30 June 2018
24th Sep 20187:00 amRNSU.S. FDA Approval IND Nasal Foralumab Phase 1
13th Sep 20181:05 pmRNSPDMR Dealing
12th Sep 20187:00 amRNSPDMR dealings
11th Sep 20187:00 amRNSPDMR Dealing
24th Aug 20187:00 amRNSPDMR Dealing
21st Aug 20187:00 amRNSPDMR dealings
20th Aug 20187:00 amRNSPDMR Dealing
17th Aug 20187:00 amRNSPDMR Dealing
16th Aug 20189:00 amRNSFiling of Investigational New Drug application
27th Jul 20187:00 amRNSUS Registration Statement for Proposed Offering
25th Jun 201810:49 amRNSResult of AGM
7th Jun 20187:01 amRNSAppointment of Broker
7th Jun 20187:00 amRNSFinal Results
1st Jun 20187:00 amRNSNotice of AGM
23rd May 20184:40 pmRNSSecond Price Monitoring Extn
23rd May 20184:35 pmRNSPrice Monitoring Extension
16th May 20187:00 amRNSMilciclib Phase 2a Trial - Tolerability Update
1st May 20183:00 pmRNSGrant of Options - Director Dealing
27th Apr 20187:00 amRNSIssue of Equity
19th Apr 20187:00 amRNSSubscription
16th Apr 20187:25 amRNSLicense Agreement
9th Apr 20188:25 amRNSPresentation at ASCO 3 June 2018
5th Apr 20187:00 amRNSAppointment of Broker
4th Apr 20187:00 amRNSAppointment of Director
5th Mar 20187:00 amRNSPlacing to raise £600,000 and issue of equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.